All news

Ionis faces shareholder investigation over guidance cut

Alpha Vantage · Morningstar · · AI-summarised by FinFlash

SueWallSt is investigating Ionis Pharmaceuticals on behalf of investors who lost money after the company cut full-year TRYNGOLZA sales guidance by more than 50% on November 9, 2026, despite beating third-quarter revenue estimates. The reduction triggered a sharp share decline and questions about statements made before the disclosure.

Read original source

IONS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.